Previsão

O preço-alvo médio dos analistas é € 99,92 (+71,39%). A mediana é € 99,47 (+70,62%).

Comprar	34
Manter	1
Vender	0

Notícias Ir para o feed de notícias

Cytokinetics added to Polaris portfolio after Myqorzo seen superior to Camzyos

Polaris Capital Management added Cytokinetics to its Q2 2026 Global Equity Strategy, citing FDA approval of Myqorzo for hypertrophic cardiomyopathy and its perceived superiority to Bristol Myers Squibb's Camzyos in symptom relief and dosing simplicity. Cytokinetics closed at $67.59 on Sept. 22, 2026, with a market cap of $9.4 billion, a 52-week range of $47.22–$88.31 and a one-month decline of 14.66% versus a 52-week gain of 39.97%. Polaris noted the company amid strong quarter-wide gains driven by AI holdings, and hedge fund ownership of Cytokinetics rose to 78 portfolios at quarter end. » Mais em finance.yahoo.com
Cytokinetics bets on MYQORZO expansion in HCM and prepares NHCM approval

At the Citigroup conference, Cytokinetics reported a better-than-expected launch for MYQORZO in obstructive HCM, capturing a 40% share of new prescriptions by the end of Q2 2026. ACACIA-HCM phase 3 data showed superiority in non-obstructive HCM (NHCM) and support a planned regulatory filing; the company estimates NHCM could represent about 50% of the HCM market. There was a slight imbalance of serious heart-failure events in ACACIA, which the company views as manageable and plans to publish additional safety data. Cytokinetics plans to increase SG&A spending to support NHCM expansion and its European roll‑out (Germany launched, UK Q4 2026, other markets in 2027) and is advancing the COMET-HF confirmatory study of Omecamtiv Mecarbil in parallel. » Mais em de.investing.com
Cytokinetics beats Q2 2026 estimates thanks to launch of MYQORZO

Cytokinetics reported a loss of $1.50 per share for Q2 2026 on revenue of $28.6 million, well above the consensus estimate of $17.09 million. The driver was the launch of the heart drug MYQORZO, which generated net product revenues of $25.3 million and treated more than 1,500 patients by the end of the quarter. The company raised its 2026 spending expectations due to increased commercial investments and holds $1.7 billion in cash. Management emphasized continued market momentum but noted risks from high costs, reliance on MYQORZO and reimbursement uncertainties. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Cytokinetics registou receitas de € 27,96 mi e um ganho líquido de -€ 174,16 mi

(EUR)	junho de 2026	YoY
Receitas	27,96 mi	50,64%
Ganho bruto	25,57 mi	53,26%
Ganho líquido	-174,16 mi	52,77%
EBITDA	-168,02 mi	83,67%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 7,25 bi
Número de ações	124,43 mi
Máximo/mínimo de 52 semanas	€ 78,43 - € 48,23
Dividendos	Não
Beta	0,36
PER (PE Ratio)	-9,10
PEG (PEG Ratio)	0,27
P/VC (PB Ratio)	-49,95
P/V (PS Ratio)	115,03

Perfil da empresa

Cytokinetics, Incorporated, ein biopharmazeutisches Unternehmen im Spätstadium der Entwicklung, konzentriert sich auf die Entdeckung, Entwicklung und Vermarktung von Muskelaktivatoren und -inhibitoren als potenzielle Behandlungsmethoden für schwächende Krankheiten. Das Unternehmen entwickelt niedermolekulare Arzneimittelkandidaten, die in erster Linie die Muskelfunktion und -kontraktilität beeinflussen sollen. Zu den Medikamentenkandidaten gehören Omecamtiv Mecarbil, ein neuartiger Herzmyosin-Aktivator, der sich in einer klinischen Phase-III-Studie bei Patienten mit Herzinsuffizienz befindet, und Reldesemtiv, ein Troponin-Aktivator für Skelettmuskeln, der sich in einer klinischen Phase-III-Studie zur Behandlung von amyotropher Lateralsklerose und spinaler Muskelatrophie befindet. Das Unternehmen entwickelt außerdem CK-136, einen neuartigen kardialen Troponin-Aktivator, der sich in der klinischen Phase I befindet; Aficamten, einen neuartigen kardialen Myosin-Inhibitor, der sich in der klinischen Phase III zur Behandlung von Patienten mit symptomatischer obstruktiver hypertropher Kardiomyopathie befindet; und CK-3772271, einen niedermolekularen kardialen Myosin-Inhibitor, der sich in der klinischen Phase I befindet. Cytokinetics, Incorporated hat eine strategische Allianz mit Astellas Pharma Inc. Das Unternehmen wurde 1997 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.

Nome	Cytokinetics
CEO	Robert I. Blum
Sede	South San Francisco, ca EUA
Site	cytokinetics.com
Setor	Materiais básicos
Indústria	Produtos químicos
Entrada em bolsa	30/04/2004
Colaboradores	673